Catalyst

Slingshot members are tracking this event:

Phase 2 additional data of Kura Oncology's(KURA) Tipifarnib in Relapsed or refractory peripheral T-cell lymphoma due at EHA

Source Link:
http://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-reports-first-quarter-2019-financial-results-and

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
KURA Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Jun 14, 2019
Occurred Source:
http://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-announces-positive-phase-2-trial-tipifarnib
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Peripheral T-cell Lymphoma, Tipifarnib
About Us
Media Center
Connect with Us
© 2025 Slingshot Insights. All rights reserved.